Call Us: +7 (495) 374-92-51

Blog

News

Dec 4
-

Sonalleve MR-HIFU Therapy platform. Advanced features in women’s health and oncology.

MR-HIFU opens up non-invasive alternatives to traditional surgical treatments of uterine fibroids and enables non-invasive palliative pain treatment of bone metastases.

It is an innovative therapy platform that integrates an advanced High Intensity Focused Ultrasound (HIFU) system into the patient table of Philips MRI systems. This allows you to perform non-invasive HIFU therapy supported by advanced planning and temperature monitoring using MR imaging.

The Sonalleve high frequency focused ultrasound uses a special transducer to focus a beam of ultrasound waves on to the fibroid located within the body. The focused ultrasound waves generate high temperatures within smaller areas. The temperature when maintained for sufficient a period of time results in the ablation of the fibroids.

hc781360-ims-ru_ru

The therapy procedure guided by Magnetic Resonance Imaging (MRI) with real time feedback helps in the focused ablation of the target location. The real-time feedback loop ensures that adequate heating takes place, treating every bit of tissue that has been targeted and volumetric ablation (a Philips proprietary technology) helps treat larger volumes efficiently and quickly.

http://www.philips.co.uk/healthcare/product/HC781360/sonalleve-mrhifu-therapy-platform

Nov 21
-

Roche launches imCORE, a global network of cancer immunotherapy centers of excellence

ImpaсOn 15 November 2016 Roche launched the global cancer immunotherapy Centers of Research Excellence (imCORE™) Network.

roche
imCORE is a global network of basic and clinical scientists from 21 leading academic research institutions in cancer immunotherapy who will work together with scientists from Roche and Genentech. This network brings together many of the world’s leading scientific and clinical experts in cancer immunotherapy to collaborate in investigating the most promising new treatment approaches. The goal is to rapidly initiate pre-clinical and clinical research based on the latest scientific discoveries and to aggregate and share data to accelerate the search for cures for people with cancer. The imCORE™ Network will focus on identifying approaches to expand the number of people who benefit from cancer immunotherapy by exploring new ways to activate a person’s immune system to fight their cancer.
http://www.roche.com/media/store/releases/med-cor-2016-11-15.htm

May 19
-

Partnership with Impact Lab

Impaсt Lab is an international company that provides highly specialized diagnostic services through a coordinated network of units which combine a profound knowledge of pathology with genetic developments. They use the most advanced molecular biology techniques for personalized prevention diagnosis and treatment.

Impaсt Lab aims to offer state-of-the-art diagnostic technologies focusing their pathologists and geneticists expertise on the patient for a tailored approach to prediction, prevention and treatment. They want to adopt the best options biotechnology and bioinformatics can offer. Impaсt Lab intends to be an open international network where the passion, knowledge and expertise of those who want to join us can be concentrated on a unique project.  

Impact Lab employs a team of medical specialists dedicated to define and follow the process of analysis and ready to support specialist practitioners in the assessment, choice and interpretation of every single test.

The test is performed by experienced biologists using state-of-the-art technologies and the most advanced molecular biology techniques. Sample management is carried out providing traceability and monitoring from receipt to result, in total respect of the strictest laboratory regulations and privacy rules. Due to automatic test results reporting, and consequent possibility for the physician to access results online, they minimize turnaround time. The using of a breakthrough technology ensures resource optimization and cost reduction with resultant lower prices which allow broader access to testing.

Being an international company, Impact Lab wants to accede to the Russian market. Impact Lab joined as well the Digital Pathology system and provides UNIM LTD. with professional consultations.

May 19
-

Partnership with Biopticka Laborator s.r.o.

Digital Pathology System began to cooperate with one of largest pathomorphology laboratories of Europe – Boipticka Laborator s.r.o. The Digital Pathology platform for telemedicine consulting was highly appreciated by many pathologists from Russia, the United States, Great Britain and Germany. The high quality of images of histopathology sections is emphasized by specialists who consult cases in different cities of Russia and foreign countries. The number of pathologists collaborating with the System grows rapidly, which leads to increasing competence of the specialists and to the development of connections among the doctors practicing in different countries.

It is necessary to underline that the Digital Pathology service is not only focused on the cooperation with individual pathologists – the UNIM LTD. company continues to expand cooperation with high-tech laboratories all over the world. Biopticka laborator s.r.o., the second largest pathomorphology laboratory in Europe, has recently joined the SAAS-platform.

Biopticka laborator s.r.o. is the largest biopsy and cytology laboratory in the Czech Republic. It performs 800,000 gynecological examinations annually, so it is one of the largest cytology laboratories in the world. Biopticka laborator s.r.o. employs internationally recognized experts, who are regularly published in top international journals, and who are invited as speakers to the European, American and world congresses. Biopticka laborator s.r.o. offers examinations of gynecological cytology (oncological and functional examination of smears from the cervix, vaginal, vulvar and endometrial mucosa) and non-gynecological cytology, biopsy, as well as complete biopsy service with a direct connection to any necessary immunohistochemical and molecular genetic testing.

Biopticka laborator s.r.o. is accredited by ČIA (Czech Institute for Accreditation) under ČSN EN ISO 15189 and holds accreditation of Ministry of Health for cervical cancer screening. The Association of health insurance companies has chosen the Biopticka laborator s.r.o. as one of the few laboratories in the Czech Republic for the program of predictive oncology, that have approved the genetic performances in pathology, such as examination of HER2/neu in breast cancer, as well as KRAS mutation of cancer of the colon and rectum.

Almost all the available funds of laboratory are reinvested in its own research, particularly in molecular genetic methods. Bioptická laboratoř s.r.o. publishes extensively. Over the last ten years of existence of the Bioptická laboratoř s.r.o., their doctors have published nearly 700 publications in top world international impacted journals (see our publications) and almost 300 articles in Czech professional journals. Almost half of the scientific articles have been published in the best American professional pathology journals.

May 19
-

Pathology Puzzles start in Europe

Pathology Puzzles is online platform for professional pathologist’s discussion and pathology cases diagnostics. We welcome oncology professionals from around the world to join us!

This project is dedicated to connect professionals with diverse expertise and experience in pathology area for the purpose of education, communication and collaboration by revealing the optimal methods of diagnosing particular cases and discussing the typical errors. Our mission for the project is to help all pathologists avoid wrong diagnostics.

Our team consists of several professionals both in pathology and software design, and we all care about pathology diagnostics development for the benefit of patient and their relatives. We believe we can make difference sharing Pathology Puzzles with you!

Pathology Puzzles is based on using the Digital Pathology© system for digital image demonstration and digital slides processing, very much like, and even better than, working with multi-head microscope. Our goal is to make it the best technology of digital pathology images sharing and diagnostics.

Every round has a leader who selects and uploads via Pathology Puzzles a number of interesting cases for discussion, such as digital histological slides, clinical data and, if necessary, the MRT, CT files available for review.

The cases are presented for registered participant’s joint discussion, and after that each participant should report the final diagnosis. At the end of every round the moderator’s report will be uploaded to the site, the results will be analyzed and the participants awarded.

Every month three new cases will be uploaded into the Digital Pathology© for review. The cases should be validated by at least two independent experts.

Don’t miss your chance to be involved in the unique non-profit project – Pathology Puzzles! We welcome oncology professionals from around the world to join Pathology Puzzles! http://pathologypuzzles.com/